Invokana Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Canagliflozin and Myocardial Micro-perfusion
Conditions:   Type 2 Diabetes;   Cardiovascular Diseases;   Cardiac Perfusion Defect Intervention:   Drug: Canagliflozin 100mg or Sitagliptin 100mg Sponsor:   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 10, 2022 Category: Research Source Type: clinical trials